drug · small molecule
linsitinib
Phase 3updated 5mo agoby Sling Therapeutics Inc🔗 ChEMBL
Phase 3community read0 votes
Small molecule drug with a maximum clinical stage of Phase 3 (across all indications), with 9 investigational indications.
targets
Insulin receptorInsulin-like growth factor 1 receptor
all catalysts(0)
nothing on the calendar yet
Trials studying linsitinib
- phase3A Phase 2b, Study of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)
- phase3Study to Assess Linsitinib in Participants With Moderate to Severe Active Thyroid Eye Disease (TED)
- phase3Extension Study of Two Doses of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)
- phase2A Rollover Study for Subjects That Have Participated in an Astellas Sponsored Linsitinib Trial
News(3)
- Sling banks $123M for an experimental thyroid eye disease pillA confirmatory late-stage study is now also underway for what the startup is positioning as, potentially, the first oral alternative to approved injectables like Amgen's Tepezza and Viridian's Lumvoa.biopharma_dive · 14d ago
- Sling catches $123M series C for thyroid eye disease pillSling Therapeutics is advancing the first late-stage oral drug for thyroid eye disease that, if approved, could compete against Amgen and Viridian Therapeutics.biospace · 14d ago
- Sling reels in $123M series C to fund oral Tepezza rival through phase 3 trialSling Therapeutics has closed a $123 million series C round to advance its oral therapy for thyroid eye disease through a phase 3 trial and hopefully on to commercialization.fiercebiotech · 15d ago
Data sources
last refreshed 3h ago
Found something off?
comments(0)
5-min edit window · permanent after that